Safety and Early Signs of Efficacy of IL12-L19L19
PH-IL12L19L19-01/19
Phase 1 other active
Quick answer
Safety and Early Signs of Efficacy of IL12-L19L19 for Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
- Phase
- Phase 1
- Modality
- other
- Status
- active